Heart Test Laboratories, Inc. AMENDMENT NO. 2 TO equity distribution AGREEMENTEquity Distribution Agreement • November 17th, 2023 • Heart Test Laboratories, Inc. • Orthopedic, prosthetic & surgical appliances & supplies
Reference is made to that certain equity distribution agreement, dated as of September 18, 2023, as amended on November 9, 2023 (the “Sales Agreement”), by and between Heart Test Laboratories, Inc., a Texas Corporation (the “Company”), and Maxim Group LLC (the “Agent”). Capitalized terms used herein but not otherwise defined are used herein as defined in the Sales Agreement.
Southlake, Texas 76092Note Conversion Agreement • November 17th, 2023 • Heart Test Laboratories, Inc. • Orthopedic, prosthetic & surgical appliances & supplies
This Note Conversion Letter Agreement (this “Agreement”), dated as of the first date written above, is entered into between Heart Test Laboratories, Inc., a Texas corporation (the “Company”), and You the undersigned holder (the “Noteholder”) of the Company’s 12% Amended and Restated Secured Promissory Note date September 29, 2023 (the “Notes”), to confirm the agreement between the Company and the Noteholder to convert such principal amount of the Noteholder’s Notes and accrued and unpaid interest due thereon, as of November 16, 2023 (as indicated on the signature page hereto) (collectively, the “Conversion Amount”), into shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at the rate of $0.16 per share (the “Conversion Price”). As an example, a Noteholder holding the Note with the Conversion Amount of $100,000 would receive upon conversion of such Note 625,000 shares of Common Stock.
Southlake, Texas 76092Note Conversion Agreement • November 17th, 2023 • Heart Test Laboratories, Inc. • Orthopedic, prosthetic & surgical appliances & supplies
This Note Conversion Letter Agreement (this “Agreement”), dated as of the first date written above, is entered into between Heart Test Laboratories, Inc., a Texas corporation (the “Company”), and You the undersigned holder (the “Noteholder”) of the Company’s Senior Unsecured Promissory Drawdown Loan Note dated September 6, 2023 (the “Notes”), to confirm the agreement between the Company and the Noteholder to convert such principal amount of the Noteholder’s Notes and accrued and unpaid interest due thereon, as of November 16, 2023 (as indicated on the signature page hereto) (collectively, the “Conversion Amount”), into shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at the rate of $0.16 per share (the “Conversion Price”). As an example, a Noteholder holding the Note with the Conversion Amount of $100,000 would receive upon conversion of such Note 625,000 shares of Common Stock.
